Entecavir maintains high genetic barrier to hepatitis B virus resistance in nucleoside-naïve patients through 5 years

¹Monash University, Clayton, Vic., Australia, ²Research & Development, Bristol-Myers Squibb, United States,₃Presidio, Pharmaceuticals, Inc., United States, and ⁴Bristol-Myers Squibb Company, Research & Development, Australia